MedTrace Logo

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

NCT03875547 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2026-04-24

No results posted yet for this study

Summary

The participants are invited to take part in this study because they have Haemophilia B. The purpose of this study is to assess the safety and effectiveness of Refixia® about long-term routine use in patients with Haemophilia B. The participants will get Refixia® as prescribed to them by their study doctor. The study will last up to Sep 2025 for the participant. The participants may be asked to fill in the quality of life questionnaires (if they are above age of 15). The blood samples taken from the participants as part of routine clinical practice will also be used to investigate the safety for the long-term use of Refixia®.

Conditions

  • Haemophilia B

Interventions

DRUG

Refixia®

Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-23
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Denmark
  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03875547 on ClinicalTrials.gov